摘要
目的探讨肝素盐水(Hep)与重组人组织型纤溶酶原激酶衍生物(r PA)治疗中央静脉导管(PICC)血栓性栓塞的临床疗效与安全性。方法选择2014年9月至2017年11月柳州市工人医院收治的148例PICC血栓性栓塞患者为研究对象,随机分为r PA组(n=74)和Hep组(n=74),2组均行溶栓治疗,观察2组再通有效率、所需时间及凝血功能变化。结果 r PA组治疗后总有效率为93.24%,Hep组总有效率为64.86%;2 h内溶栓再通分别为75.67%和54.35%,差异均具有统计学意义(P<0.05)。r PA组纤维蛋白原(FIB)再通前后比较减少明显,差异有统计学意义(P<0.05),但仍在正常值范围内,且未出现出血现象。结论对PICC血栓性栓塞溶栓采取r PA进行治疗,能快速、安全作用于血栓,效果显著。
Objective To investigate the clinical efficacy and safety of Hep and r PA in the treatment of PICC thrombotic embolism. Methods 148 patients with PICC thrombotic embolism treated in Liuzhou Worker＇s Hospital from September 2014 to November 2017 were selected as the research subjects.These were randomly divided into group r PA（n=74） and group Hep（n=74）. The 2 groups were treated with thrombolytic therapy. Observed 2 groups of recanalization efficiency, required time and coagulation function changes. Results The total effective rate after treatment in group r PA was 93.24%, and the total effective rate in group Hep was 64.86%. The thrombolytic recanalization in 2 h was 75.67% and 54.35% respectively, and the difference was statistically significant（P〈0.05）.The fibrinogen（FIB） in group r PA was significantly reduced before and after recanalization. The difference was statistically significant（P〈0.05）. But it is still within the range of normal value, and there is no bleeding phenomenon. Conclusion r PA was used to treat thrombolytic thrombolysis in PICC, a rapid and safe effect on thrombus has been achieved.
作者
郑毅
侯培勇
冯培芳
蓝宇俭
叶奕辉
Zheng Yi;Hou Peiyong;Feng Peifang;Lan Yujian;Ye Yihui(Department of Vascular Surgery,Liuzhou Worker＇s Hospital,Liuzhou 545005,Guangxi Chin)
出处
《血管与腔内血管外科杂志》
2018年第1期81-84,94,共5页
Journal of Vascular and Endovascular Surgery
基金
广西壮族自治区卫生和计划生育委员会自筹经费科研课题(Z20170907)
关键词
重组人组织型纤溶酶原激酶衍生物
肝素盐水
外周静脉置入中央静脉导管
血栓性栓塞
recombinant human tissue-typeplasminogen activator derivative for injection
Heparin solution
peripherallyinserted central catheter
thromboembolic embolism
